developed anti-B7-H3/PD-1 bispecific fusion proteins that simultaneously engaged the tumor-associated marker B7-H3 and the immune-suppressing ligand PD-L1 and enhanced ADCC to promote potent and highly selective tumor killing (98). This evidence concerns the gene CD276 and neoplasm.